Second Sight Medical Products EYES shares are trading higher Tuesday after the company announced that it was issued a U.S. Patent for the uses of eye-tracking in a visual prosthesis.
Second Sight Medical Products develops, manufactures and markets implantable prosthetic devices, to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP.
Second Sight Medical Products shares traded up 18.17% to $2.47. The stock has a 52-week high of $6.40 and a 52-week low of 69 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
